Senores Pharmaceuticals Ltd - IPO

Senores Pharmaceuticals Ltd IPO Details

Initial public offering of 14,887,723 equity shares of face value of Rs. 10 each (Equity Shares) of Senores Pharmaceuticals Limited (The Company or the Issuer) for cash at a price of Rs. 391 per equity share (including a share premium of Rs. 381 per equity share) (Offer Price) aggregating to Rs. 582.11 crores (the Offer). The offer comprises of a fresh issue of 12,787,723 equity shares by the company aggregating to Rs. 500.00 crores (the Fresh Issue) and an offer for sale of 2,100,000 equity shares (the Offered Shares) aggregating to Rs. 82.11 crores (the Offer for Sale), comprising 250,000 equity shares aggregating to Rs. 9.78 crores by Swapnil Jatinbhai Shah, 550,000 equity shares aggregating to Rs. 21.51 crores by Ashokkumar Vijaysinh Barot, 300,000 equity shares aggregating to Rs. 11.73 crores by Sangeeta Mukur Barot and 1,000,000 equity shares aggregating to Rs. 39.10 crores by Prakash M Sanghvi (the Selling Shareholders). The offer shall constitute 32.33 % of the post-offer paid-up equity share capital of the company. The offer includes a reservation of 75,000 equity shares, aggregating to Rs. 2.93 crores constituting 0.16% of the post-offer paid-up equity share capital, for subscription by eligible employees (Employee Reservation Portion). The offer less the employee reservation portion is hereinafter referred to as the Net Offer. The face value of the equity shares is Rs. 10 each and the offer price is 39.10 times the face value of the equity shares.

Objective of issue

Funding the capital expenditure requirements by investment in of one of your its subsidiary Havix,for setting up a mfg facility for the production of sterlie injection in its Atlanta Facility. Re-payment/pre-payment in full or in part of certain borrowings availed by the company and its subsidiary namely Havix Ratnatris and PSI. Funding the working capital requirements of the company and its subsidiary namely SPI ad Ratnatris. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes. Investment in its subsidiary namely Havix for re-payment/pre-payment in full or in part of certain borrowings availd by the subsidiaries. Investment in its subsidiary namely SPI and Ratnatri to fund their working capital requirements.

Senores Pharmaceuticals Ltd Contact Details

Senores Pharmaceuticals Ltd, C-101 247 Park, L B S Marg, Vikhroli West, Mumbai-400083

Phone - 91-22-49186000

Fax - 91-22-49186060

Email - cs@senorespharma.com

Website - www.senorespharma.com